– Achieved $21.0 million in OGSIVEO® net product revenue in the first quarter – – Received validation from the EMA for MAA of nirogacestat for the treatment of adults with desmoid tumors – .
– Reported OGSIVEO™ net product revenue of $5.4 million in first partial quarter of launch following FDA approval on November 27, 2023 – – Submitted Marketing Authorization Application to.
SpringWorks Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.
SpringWorks Therapeutics, Inc : SpringWorks Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
– NDA for Nirogacestat in Adults with Desmoid Tumors Accepted by the FDA and Granted Priority Review; PDUFA Action Date Set for August 27, 2023 – – Phase 3 DeFi Trial Evaluating. | May 3, 2023